新冠病毒 mRNA 疫苗接种后的心肌炎：临床观察及潜在机制。
Myocarditis after COVID-19 mRNA vaccination: clinical observations and potential mechanisms.
机构信息
Maastricht University Medical Centre, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, Netherlands.
Department of Cardiovascular Medicine, Mayo Clinic in Florida, Jacksonville, FL, USA.
出版信息
Nat Rev Cardiol. 2022 Feb;19(2):75-77. doi: 10.1038/s41569-021-00662-w.
Abstract
The risk of acute myocarditis associated with COVID-19 mRNA vaccination has garnered intense (social) media attention. However, myocarditis after COVID-19 mRNA vaccination is rare and usually resolves within days or weeks. Moreover, the risks of hospitalization and death associated with COVID-19 are greater than the risk associated with COVID-19 vaccination. Therefore, COVID-19 vaccination should be recommended in adolescents and adults.
摘要
与 COVID-19 mRNA 疫苗接种相关的急性心肌炎的风险引起了（社会）媒体的强烈关注。然而，COVID-19 mRNA 疫苗接种后的心肌炎很少见，通常在数天或数周内即可痊愈。此外，COVID-19 住院和死亡的风险大于 COVID-19 疫苗接种的风险。因此，应建议青少年和成年人接种 COVID-19 疫苗。
相似文献
1
Myocarditis after COVID-19 mRNA vaccination: clinical observations and potential mechanisms.
Nat Rev Cardiol. 2022 Feb;19(2):75-77. doi: 10.1038/s41569-021-00662-w.
2
Myocarditis Cases After mRNA-Based COVID-19 Vaccination in the US.
JAMA. 2022 May 24;327(20):2019-2020. doi: 10.1001/jama.2022.5131.
3
Myocarditis Cases After mRNA-Based COVID-19 Vaccination in the US-Reply.
JAMA. 2022 May 24;327(20):2020-2021. doi: 10.1001/jama.2022.5134.
4
Features of Inflammatory Heart Reactions Following mRNA COVID-19 Vaccination at a Global Level.
Clin Pharmacol Ther. 2022 Mar;111(3):605-613. doi: 10.1002/cpt.2499. Epub 2021 Dec 27.
5
Meta-Analysis of Risk of Myocarditis After Messenger RNA COVID-19 Vaccine.
Am J Cardiol. 2022 Mar 15;167:155-157. doi: 10.1016/j.amjcard.2021.12.007. Epub 2022 Jan 19.
6
Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices - United States, June 2021.
MMWR Morb Mortal Wkly Rep. 2021 Jul 9;70(27):977-982. doi: 10.15585/mmwr.mm7027e2.
7
Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review.
BMJ. 2022 Jul 13;378:e069445. doi: 10.1136/bmj-2021-069445.
8
Two Cases of Acute Myocarditis in Young Male Adults After mRNA Vaccines Against COVID-19: Similarities and Differences.
Med Arch. 2022 Jun;76(3):215-220. doi: 10.5455/medarh.2022.76.215-220.
9
Definite Acute Myocarditis After Coronavirus Disease 2019 mRNA Vaccination.
Circ J. 2022 Mar 25;86(4):724. doi: 10.1253/circj.CJ-21-0840. Epub 2021 Dec 4.
10
Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with multiple myeloma.
BMC Cancer. 2021 Dec 27;21(1):1354. doi: 10.1186/s12885-021-09097-5.
引用本文的文献
1
Rural-Urban Disparities in COVID-19 Vaccine Uptake and Associated Mortality and Cardiovascular Disease Outcomes in the United States.
Vaccines (Basel). 2025 Aug 14;13(8):861. doi: 10.3390/vaccines13080861.
2
The early impact of COVID-19 vaccines on major events in cardiac, pulmonary, and thromboembolic disease: a population-based study.
Korean J Intern Med. 2025 Sep;40(5):801-812. doi: 10.3904/kjim.2025.056. Epub 2025 Aug 26.
3
Myocarditis Following COVID-19 Vaccine: What Did We Learn?
Sage Open Pediatr. 2025 Jun 20;12:30502225251336877. doi: 10.1177/30502225251336877. eCollection 2025 Jan-Dec.
4
Cardiopulmonary Effects of COVID-19 Vaccination: A Comprehensive Narrative Review.
Vaccines (Basel). 2025 May 22;13(6):548. doi: 10.3390/vaccines13060548.
5
The New Era of mRNA Vaccines: The Success of the COVID-19 Vaccines and the Safety Concerns in Adolescents.
Indian J Community Med. 2025 May-Jun;50(3):404-406. doi: 10.4103/ijcm.ijcm_544_23. Epub 2024 Nov 13.
6
Considerations for mRNA Product Development, Regulation and Deployment Across the Lifecycle.
Vaccines (Basel). 2025 Apr 28;13(5):473. doi: 10.3390/vaccines13050473.
7
COVID-19 and Diabetes: Persistent Cardiovascular and Renal Risks in the Post-Pandemic Landscape.
Life (Basel). 2025 Apr 30;15(5):726. doi: 10.3390/life15050726.
8
Global, regional, and national burden of myocarditis and its attributable risk factors in 204 countries and territories from 1990 to 2021: updated systematic analysis.
Front Public Health. 2025 Apr 28;13:1542921. doi: 10.3389/fpubh.2025.1542921. eCollection 2025.
9
The COVID-19 pandemic in children and young people during 2022-24: what new did we learn?
J Glob Health. 2025 Apr 2;15:01002. doi: 10.7189/jogh.15.01002.
10
A case report of severe myocarditis combined with erythema multiforme caused by herpes simplex virus-1.
Front Cardiovasc Med. 2025 Mar 12;12:1421364. doi: 10.3389/fcvm.2025.1421364. eCollection 2025.
本文引用的文献
1
Myocarditis after Covid-19 Vaccination in a Large Health Care Organization.
N Engl J Med. 2021 Dec 2;385(23):2132-2139. doi: 10.1056/NEJMoa2110737. Epub 2021 Oct 6.
2
Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel.
N Engl J Med. 2021 Dec 2;385(23):2140-2149. doi: 10.1056/NEJMoa2109730. Epub 2021 Oct 6.
3
Myocardial Pathology in COVID-19-Associated Cardiac Injury: A Systematic Review.
Diagnostics (Basel). 2021 Sep 8;11(9):1647. doi: 10.3390/diagnostics11091647.
4
Surveillance for Adverse Events After COVID-19 mRNA Vaccination.
JAMA. 2021 Oct 12;326(14):1390-1399. doi: 10.1001/jama.2021.15072.
5
Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military.
JAMA Cardiol. 2021 Oct 1;6(10):1202-1206. doi: 10.1001/jamacardio.2021.2833.
6
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.
N Engl J Med. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389. Epub 2020 Dec 30.
7
Predictors of Mortality in Patients With Biopsy-Proven Viral Myocarditis: 10-Year Outcome Data.
J Am Heart Assoc. 2020 Aug 18;9(16):e015351. doi: 10.1161/JAHA.119.015351. Epub 2020 Aug 13.
8
Myocardial injury characterized by elevated cardiac troponin and in-hospital mortality of COVID-19: An insight from a meta-analysis.
J Med Virol. 2021 Jan;93(1):51-55. doi: 10.1002/jmv.26108. Epub 2020 Jun 19.
9
Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases.
Clin Immunol. 2020 Aug;217:108480. doi: 10.1016/j.clim.2020.108480. Epub 2020 May 24.
10
The Quest for New Approaches in Myocarditis and Inflammatory Cardiomyopathy.
J Am Coll Cardiol. 2016 Nov 29;68(21):2348-2364. doi: 10.1016/j.jacc.2016.09.937.
Zotero 插件